National Institute of Neurological Disorders and Stroke (NINDS)
ninds.nih.govLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
600
Active
59
Phase 3
17
Total enrollment
109,054
Pipeline matrix
Showing 18 of 18 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| methylprednisolone | — | — | — | — | 2 | ||
| Teriflunomide | — | — | — | — | — | 1 | |
| Brincidofovir | — | — | — | — | — | 1 | |
| Resiniferatoxin | — | — | — | — | — | 1 | |
| LMP744 | — | — | — | — | — | 1 | |
| IV normal saline | — | — | — | — | — | 1 | |
| IV immunoglobulin | — | — | — | — | — | 1 | |
| Prednisone | — | — | — | — | — | 1 | |
| Mangafodipir | — | — | — | — | — | 2 | |
| Acamprosate calcium | — | — | — | — | — | 1 | |
| 89 Zr-Df-crefmirlimab | — | — | — | — | — | 1 | |
| Keytruda | — | — | — | — | — | 1 | |
| Gadolinium | — | — | — | — | — | 1 | |
| 13N-Ammonia | — | — | — | — | — | 2 | |
| 18F-DOPA | — | — | — | — | — | 1 | |
| 11C-Methylreboxetine | — | — | — | — | — | 1 | |
| 18F-Dopamine | — | — | — | — | — | 1 | |
| Desmopressin acetate | — | — | — | — | — | 1 |
Next readouts
- 2026-12-01
- 2026-12-15
- 2027-09-30
- 2027-12-31
- 2028-01-01
- 2028-02-26
- 2028-12-31
- 2028-12-31
- 2029-12-31
- 2030-04-01
Top conditions
- Healthy94
- Parkinson Disease33
- Epilepsy31
- Stroke27
- Multiple Sclerosis27
- Parkinson's Disease26
- Cerebrovascular Accident25
- Focal Dystonia21
Frequently asked questions about National Institute of Neurological Disorders and Stroke (NINDS)
- How many clinical trials does National Institute of Neurological Disorders and Stroke (NINDS) have on ClinicalTrials.gov?
- National Institute of Neurological Disorders and Stroke (NINDS) is listed as the lead sponsor on 600 clinical trials in ClinicalTrials.gov, 59 of which are currently active (recruiting, enrolling, or ongoing).
- How many of National Institute of Neurological Disorders and Stroke (NINDS)'s trials are in Phase 3?
- 17 of National Institute of Neurological Disorders and Stroke (NINDS)'s trials are in Phase 3, spread across 18 active drug programs.
- What therapeutic areas does National Institute of Neurological Disorders and Stroke (NINDS) focus on?
- National Institute of Neurological Disorders and Stroke (NINDS)'s most-studied conditions on ClinicalTrials.gov are Healthy, Parkinson Disease, Epilepsy, Stroke, Multiple Sclerosis.
- When are National Institute of Neurological Disorders and Stroke (NINDS)'s next clinical trial readouts?
- National Institute of Neurological Disorders and Stroke (NINDS) has 10 upcoming primary-completion readouts tracked here; the soonest is “Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain”, expected around 2026-12-01.